Marker Therapeutics (NASDAQ:MRKR – Get Free Report) had its price objective boosted by LADENBURG THALM/SH SH from $11.00 to $19.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price target would indicate a potential upside of 318.50% from the company’s previous close.
Marker Therapeutics Stock Performance
Marker Therapeutics stock opened at $4.54 on Monday. The stock’s 50-day moving average is $3.09 and its 200-day moving average is $3.97. Marker Therapeutics has a 12 month low of $2.40 and a 12 month high of $6.16.
Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.25) EPS for the quarter. The firm had revenue of $1.17 million during the quarter. Marker Therapeutics had a negative return on equity of 78.91% and a negative net margin of 278.27%. Sell-side analysts expect that Marker Therapeutics will post -1.43 EPS for the current year.
Institutional Investors Weigh In On Marker Therapeutics
Marker Therapeutics Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.
Further Reading
- Five stocks we like better than Marker Therapeutics
- How to Use the MarketBeat Dividend Calculator
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Short Selling: How to Short a Stock
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.